Sunday, September 8, 2019		
08h00–21h00	Congress registration	16h00–21h00 Exhibition
10h30–16h00	**Continuing Education Courses (CEC),** including coffee & lunch breaks	
10h30–16h00	**CEC1** **Development and evaluation of AOPs** **Chairs:** Sharon Munn, Italy | Bette Meek, Canada **AOP Background and Principles** Sharon Munn, EU Joint Research Centre, Italy **AOP wiki and live demonstration** Clemens Wittwehr, European Commission, DG JRC, Italy **Weight of Evidence/Confidence Evaluation for AOPs** Bette Meek, University of Ottawa, Canada **Application of AOPs to consider biological plausibility of associations observed in epidemiological studies: exposure to pesticides and Parkinson's disease** Andrea Terron, European Food Safety Authority, Italy **Application of AOPs for the development of Defined Approaches (DA) and Integrated Approaches to Testing and Assessment (IATA)** Gavin Maxwell, Unilever, UK	
10h30–16h00	**CEC2** **Application and integration of increasingly mechanistically driven tools for risk assessment** **Chairs:** Richard Brown, Switzerland | Bette Meek, Canada **Overview of WHO chemical risk assessment methodology tools** Richard Brown, WHO, Switzerland **Characterizing uncertainty in hazard characterization: principles and approach developed by the WHO/IPCS** Matthias Herzler, Federal Institute for Risk Assessment (BfR), Germany **Mode of action/adverse outcome pathway analysis**	

	George Fotakis, European Chemicals Agency (ECHA), Finland **Application and utility of chemical-specific adjustment factors in risk assessment** Virunya Bhat, WHO Collaborating Centre on Water and Indoor Air Quality and Food Safety at NSF International, US **Combined Exposures to Multiple Chemicals; Tiered Integration of Tools** Bette Meek, University of Ottawa, Canada
10h30–16h00	**CEC3** **The pre-specified protocol part of evidence-based assessment in toxicology** **Chairs:** George Kass, Italy | N. N. **The role of a pre-specified protocol in evidence-based assessments** George Kass, EFSA, Italy **Scoping, literature search strategy, inclusion and exclusion criteria** Rex FitzGerald, University of Basel, Switzerland **Assessing internal validity** Annika Hanberg, Institute of Environmental Medicine (IMM), Sweden **Summarizing and synthesizing the evidence** Ursula Gundert-Remy, Charité Berlin, Germany **Aspects of weight of evidence** Detlef Wölfle, Germany
10h30–16h00	**CEC4** **Real world safety assessments for data-poor products: How to approach data gaps** **Chairs:** Heli Miriam Hollnagel, Switzerland | N. N. **Properties of typical products requiring safety assessments: Focus on non-intentionally added substances (NIAS)** Thomas Gude, SQTS, Switzerland **Quantitative structure-activity relationship (QSAR) and grouping approaches such as read-across and category formation** Mark Cronin, John Moores University, UK

	Thresholds of toxicological concern (TTC) Heli Miriam Hollnagel, Dow Europe, Switzerland ***In vitro* assays: Validated assays for regulatory purpose versus explorative assays for Research & Development and high throughput** Manfred Tacker, University of Applied Sciences Vienna, Austria **Data sources for exposure assessment** Tatsiana Dudzina, ExxonMobil Biomedical Science Inc., Belgium
10h30–16h00	**CEC5** **Dietary exposure assessment** ***Supported by the Finnish Food Safety Authority*** **Chairs:** Tero Hirvonen, Finland | N. N. **Dietary exposure assessment: an overview** Davide Arcella, European Food Safety Authority, Italy **Unravelling the chemical information hiding in our food** Stefan Voorspoels, Flemish Institute for Technological Research (VITO), Belgium **Food consumption data** Liisa Valsta, National Institute for Health and Welfare, Finland **Total diet studies: benefits and challenges** Véronique Sirot, ANSES (French Agency for Food, Environmental and Occupational Health & Safety), France **Dietary exposure modelling: MCRA software** Polly Boon, RIVM, Netherlands **Statistical modelling: BIKE Model** Jukka Ranta, Finnish Food Safety Authority, Finland
10h30–16h00	**CEC6** **Determining safe exposure limits in occupational toxicology, application to pharmaceuticals**

	Chairs: Nancy Claude, France | Ester Lovsin-Barle, Switzerland **Key elements of reliable risk assessment of chemicals** Corrado Galli, University of Milan, Italy **Regulatory perspective on application of health based exposure limits (HBEL) in drug manufacturing** Daniel Roth, Swissmedic, Switzerland **Derivation of acceptable daily exposures (ADE) or Occupational exposure limits (OEL) – An industry approach** Thomas Pfister, F. Hoffmann-La Roche, Switzerland **Overcoming data gaps: Generic versus substance-specific approaches in health based exposure limit (HBEL) setting** Ester Lovsin-Barle, Lonza, Switzerland **Case study, special end points, route to route extrapolation** Camille Jandard, Servier, France **Determining safe exposure limits in occupational toxicology, application to pharmaceuticals** Tim Bowner, ECHA, Finland
10h30–16h00	**Satellite Meeting by ECETOC** **"Hazard Identification, Classification and Risk Assessment of Carcinogens: Too Much or Too Little?"** *(Attendance is free of charge but an additional registration is required)*
16h00	**Opening of the exhibition**
17h00–19h00	**Opening Ceremony** incl. **Keynote Lecture 1** and **EUROTOX Merit Award**
19h00–21h00	**Welcome Reception** in the exhibition area
Monday, September 9, 2019	
08h00–18h00	Congress registration | 09h00–16h30 Exhibition
09h00–10h00	**Keynote Lecture 2**
10h00–10h30	Coffee Break, **Exhibition** & **Poster Viewing 1**
10h30–12h30	**Session 1** **Metabolic capacity and functionality of the gut microbiome** ***Supported by ECETOC***

	Chairs: Bennard van Ravenzwaay, Germany | Karsten Beekmann, Netherlands **Determining the role of the gut microbiota in the toxicity of foodborne chemicals in *vitro*** Karsten Beekmann, Wageningen University of Research, Netherlands **Metabolomic applications to decipher gut microbial metabolic influence in health and disease** François-Pierre Martin, Nestlé Institute of Health Sciences, Switzerland **Influence of the microbiome on plasma metabolite patterns – an inter-omic approach** Christina Behr, BASF & Wageningen University of Research, Germany **Contribution of the gut microbiome to host endogenous and xenobiotic metabolism and the carcinogenic potential of the micro-biome** Jonathan Swann, Imperial College London, UK
10h30–12h30	**Session 2** **Fetus – the most sensitive individual** **Chairs:** Kirsi Vähäkangas, Finland | N. N. **Fetal exposure to toxic compounds** Kirsi Vähäkangas, University of Eastern Finland, Finland **Environment and male reproductive health** Niels Skakkebaek, Rigshospitalet Copenhagen, Denmark **Epigenetics in fetal susceptibility to toxicity** Juliette Legler, Utrecht Institute for Pharmaceutical Sciences (UIPS), Netherlands **Future trends in testing for developmental toxicity** Aldert Piersma, RIVM, Bilthoven, Netherlands
10h30–12h30	**Session 3** **The exposome – understanding the role of environmental exposure in human health and disease** **Chairs:** Angela Mally, Germany | N. N. **EXPOsOMICS: Novel approach to the assessment of exposure to high priority environmental pollutants**

	Paolo Vineis, Imperial College London, UK **Chemical exposure metabolomics** Benedikt Warth, University of Vienna, Austria **The human early-life exposome and its link to children's health** Rémy Slama, INSERM, France **Developing the regulatory utility of the exposome** Elaine Faustman, University of Washington, US
10h30–12h30	**Session 4** **How innate immune cells recognize toxicants** **Chairs:** François Huaux, Belgium | N. N. **Innate cells sense toxicants as microorganisms** François Huaux, Université catholique de Louvain, Belgium **Lessons for toxicology from pathogen sensing by the innate immunity** Mohamed Lamkanfi, Ghent University, Belgium **Metal-induced immunotoxicity: ionic metals, innate immune receptors and skin allergy** Marc Pallardy, Université de Paris-Sud, France **Scavenger receptors recognize toxicants** Andrij Holian, University of Montana-Missoula, US **Revisiting the paradigm of particle toxicity: surface disorder and membranolysis;** **Revisiting the paradigm of silica pathogenicity with synthetic quartz crystals: the role of crystallinity and surface disorder.** Francesco Turci, University of Torino, Italy
10h30–12h30	**Session 5** **New tools and application in reg. risk assessment – moving toward mechanistic risk assessment** ***Supported by EU-ToxRisk Project*** **Chairs:** Bob van de Water, Netherlands | N. N. **Development of *in vitro* tests – Quality assurance and cross system testing**

	Marcel Leist, University of Konstanz, Germany **Modeling the impact of several *in vitro* systems in a read-across approach – applicability of the Dempster Shafer Theory** Ulf Norinder, SweTox, Sweden **Incorporating QIVIVE and PBTK into toxicity testing and assessment** Ciaran Fisher, SIMCYP, UK **Development of qualitative and quantitative AOPs and their integration into risk assessment** Frédéric Bois, INERIS, France **Integrate NAMs into reg. risk assessment – experiences from read-across case studies** Sylvia Escher, Fraunhofer ITEM, Germany
12h30–13h30	Lunch Break, **Exhibition** & **Poster Viewing 1**
13h30–14h30	**EUROTOX–SOT Debate**
14h30–15h00	Coffee Break, **Exhibition** & **Poster Viewing 1**
15h00–17h00	**Session 6** **Developments in the use of systematic review in chemical risk assessment** ***Supported by Eurotox Risk Assessment Speciality Section (ERASS)*** **Chairs:** Richard Brown, Switzerland | Chris Weis, US **Principles of using systematic review methods in chemical risk assessment** Annika Hanberg, Karolinska Institute, Sweden **Getting the balance right between objectives and resources for a systematic review – the importance of problem formulation** Martin Wilks, University of Basel, Switzerland **Use of systematic review methods by national programmes – examples from the USA** Chris Weis, US Government (NIEHS), US **Systematic review, evidence and decision-making – experience from WHO** Angelika Tritscher, WHO, Switzerland

15h00–17h00	**Session 7** **Speeding up hazard assessment of nanomaterials** **Chairs:** Bengt Fadeel, Sweden | N. N. **Hazard assessment of engineered nanomaterials: setting the scene** Bengt Fadeel, Karolinska Institutet Stockholm, Sweden **High-content/high-throughput screening of nanomaterials** Carsten Weiss, Karlsruhe Institute of Technology, Germany **Systems biology approaches for nanomaterial hazard classification** Dario Greco, University of Tampere, Finland **Systems toxicology to support development of adverse outcome pathways** Roland Grafström, Misvik Biology Turku, Finland
15h00–17h00	**Session 8** **Human adaptation to environmental pollution: dose-response relationship revisited** **Chairs:** Pavel Rossner, Czech Republic | Alberto Izzotti, Italy **Hormesis: Scientific foundations and its implications for biology, toxicology and medicine** Edward J. Calabrese, University of Massachusetts, US **Biomarkers for adaptive responses: how toxicology changes into pharmacology** Aalt Bast, Maastricht University, Netherlands **Clues to adaptation of the human population to the environment: lessons from Czech biomonitoring studies** Pavel Rossner, Institute of Experimental Medicine Prague, Czech Republic **MicroRNA response to environmental carcinogens: from adaptation to damage** Alberto Izzotti, University of Genoa, Italy
15h00–17h00	**Session 9** **Application of new approach methods and development of integrated approaches to testing and assessment – moving toward mechanistic risk assessment** ***Supported by EU-ToxRisk Project***

	Chairs: Hennicke Kamp, Germany | Bob van de Water, Netherlands **Read-across concept in EU-ToxRisk and integration of new approach methods into risk assessment – example branched carboxylic acids** Sylvia Escher, Fraunhofer ITEM, Germany **Integration of new approach methods in a structure based read-across for DART effects** Dinant Kroese, TNO, Netherlands **Learnings from EU-ToxRisk read-across case studies: application of new approach methods** Bob van de Water, Leiden University, Netherlands **Ab initio- prediction of liver toxicity by *in vitro* systems and spatio-temporal modelling** Jan Hengstler, IFADO, Germany
15h00–17h00	**Session 10** **The process of ageing and its modulation: telomeres as biomarkers in *in vitro* and *in vivo* studies** **Chairs:** Aristidis M. Tsatsakis, Greece | Félix Carvalho, Portugal **Clinical aspects of Precision Medicine using as biomarkers telomere length, fatty acids and organic acids** Dimitris Tsoukalas, E.I.Nu.M., Greece **Low grade chronic inflammation and telomere shortening: immunosenescence process in human** Ayse Basak Engin, Gazi University, Turkey **Live fast, die young mode: influence of substance abuse on telomeres and telomerase** Félix Carvalho, University of Porto, Portugal **Telomeres biology involvement in thyroid neoplasia: from aging clock to aggressive cancers** Corin Badiu, The Romanian Society of Psychoneuroendocrinology, Romania
17h00–18h00	**Speciality Section Meetings**
19h30–21h30	**City Hall Reception,** *sponsored by the City of Helsinki*

Tuesday, September 10, 2019		
08h00–18h00	Congress registration	09h00–16h30 Exhibition
09h00–10h00	**SOT Merit Award Lecture**	
10h00–10h30	Coffee Break, **Exhibition** & **Poster Viewing 2**	
10h30–12h30	**Session 11** **Challenges of non-animal approaches for food safety: from inception to application** ***Supported by ILSI*** **Chairs:** Alan Boobis, UK | Anette Thiel, Switzerland **High throughput screening in the risk and benefit assessment of food ingredients** Ans Punt, RIKILT, Netherlands **Adverse outcome pathways and beyond** Mathieu Vinken, Vrije Universiteit Brussel, Belgium **Strategies for avoiding animal testing in food safety and efficacy evaluation: challenges and opportunities** Bob van de Water, Leiden University, Netherlands **Regulatory perspective on non-animal approaches to assess foods and food ingredients** Katrin Schutte, European Commission – DG Environment, Belgium	
10h30–12h30	**Session 12** **Implications of biodistribution of inhaled nanoparticles: effects in organs other than the lung** **Chairs:** Karin Sørig Hougaard, Denmark | Flemming Cassee, Netherlands **The lung as a barrier to inhaled particles: dosimetry and biodistribution** Flemming Cassee, RIVM, Netherlands **Effects of particles on the central nervous system** Roel Schins, Leibniz Research Institute for Environmental Medicine, Germany **Effects of particles on the placenta and fetus** Luisa Campagnolo, University of Rome, Italy	

	Effects of particles on male and female fertility Karin Sørig Hougaard, Danish Centre for Nanosafety, Denmark
10h30–12h30	**Session 13** **Knowledge-based computational approaches in predictive toxicology** ***Supported by EU-H2020*** **Chairs:** Ferran Sanz, Spain | Thomas Steger-Hartmann, Germany **The power of workflows - toxicological read across using the Open PHACTS discovery platform** Gerard F. Ecker, University of Vienna, Austria **Integrating explicit knowledge and statistics in the *in silico* modelling** Emilio Benfenati, IRFMN, Italy **Predicting with confidence: Toxicological *in silico* model building and prediction using Conformal Prediction** Ulf Norinder, SweTox, Sweden **Small is beautiful: application of local models in toxicology** Manuel Pastor, University Pompeu Fabra, Spain
10h30–12h30	**Session 14** **Understanding the interindividual variability in toxicity involving the psychotropic drugs** **Chairs:** Bruno Mégarbane, France | N. N. **Psychotropic drug poisonings admitted to the emergency department: epidemiology and morbidities** Pieter de Paepe, University Hospital Ghent, Belgium **Drug-induced toxicity at therapeutic doses versus acute overdose: physiopathological differences** Florian Eyer, Technical University of Munich, Germany **Alcohol poisonings: understanding inter-individual toxicokinetic differences and effect variations** Ana Ferrer-Dufol, Zaragoza University, Spain **Lithium poisoning: how the ingestion pattern can modify its neuropharmacokinetics and neurotoxicity** Bruno Mégarbane, Paris-Diderot University, France

10h30–12h30	**Session 15** **Investigative Toxicology Leaders Forum (ITLF): Scientific advancements and case studies for the optimization of drug discovery. Trends in investigative toxicology** **Chairs:** Teija Oinonen, Finland | Thomas Steger-Hartmann, Germany **Olson revisited – Translational Analysis of Safety Data (IMI eTRANSAFE)** François Pognan, Novartis Pharma AG, Switzerland **Application of *in vitro* pharmacokinetic simulations using "microformulator" technology for quantified risk assessments** Clay Scott, AstraZeneca, US **Development of 3D eye models for early assessment of retinal toxicity. A CRACK-IT Challenge** Philip Hewitt, Merck KGaA/ERT, Germany **Development of *in vitro* systems for ADC toxicity** Katja Hempel, AbbVie, Germany
12h30–13h30	Lunch Break, **Exhibition** & **Poster Viewing 2**
13h30–14h30	**ILSI/HESI Lecture**
14h30–15h00	Coffee Break, **Exhibition** & **Poster Viewing 2**
15h00–17h00	**Session 16** **Chemical risk assessment using human *in vitro*, *ex vivo*, *in silico* and biomonitoring data** ***Supported by the Danish Society of Pharmacology and Toxicology*** **Chairs:** Anne Marie Vinggaard, Denmark | N. N. **Chemical risk assessment: How well do human *in vitro* and *in silico* data predict the *in vivo* situation?** Richard Judson, EPA, US **PBK modeling for chemical risk assessment: *in vitro* biomarkers for developmental toxicity and their extrapolation to the *in vivo* situation** Yvonne Rietjens, Waageningen University, Netherlands **Prediction of adverse male reproductive health effects using *in vitro* tests and PBK modelling**

	Anne Marie Vinggaard, Technical University of Denmark/SSCT & ESTIV, Denmark **Human biomonitoring and complex serum mixture effects as biomarkers of impact on fetal growth** Eva Bonefeld-Jørgensen, Aarhus University, Denmark
15h00–17h00	**Session 17** **Experimental comprehensive toxicological studies simulating real-life exposures: Long-term combined exposures on multi end-points** **Chairs:** Aristidis M Tsatsakis, Greece | Antonio Hernández, Spain **Experimental designs and protocols from methodology to application: problems and solutions** Anca O. Docea, University of Medicine and Pharmacy Craiova, Romania **Oxidative stress biomarkers in long-term toxicity studies of combined exposures** Dimitrios Kouretas, University of Thessaly, Greece **Comparative evaluation and challenges in translating endpoints from experimental studies to human epidemiological observations** Antonio Hernández, University of Granada School of Medicine, Spain **The concept of Toxicology safety evaluations in 21st century** Aristidis M Tsatsakis, University of Crete, Greece
15h00–17h00	**Session 18** **Biomarkers in predictive toxicology and risk assessment** **Chairs:** Eugenia Dogliotti, Italy | N. N. **The exposome in practice** Paolo Vineis, Imperial College St Mary's London, UK **Microfluidic systems to identify new biomarkers** Henriette Lanz, Mimetas – The Organ on a Chip Company, Netherlands **Lessons learnt from 'omics' technologies *in vivo* in the last decades** Heidrun Ellinger-Ziegelbauer, Bayer AG, Germany

	Use of biomarkers in the assessment of risk from environmental contamination by perfluorinated compounds: strengths and weaknesses Tony Fletcher, Public Health England, UK
15h00–17h00	**Session 19** **Endocrine disruption: identification of root causes** ***Supported by ECETOC*** **Chairs:** Bennard van Ravenzwaay, Germany | N. N. **ED identification and the use of weight of evidence** John Doe, ECETOC, Belgium **Dose-response relationship of single and combined exposure to ED chemicals *in vitro* & *in vivo*** Steffen Schneider, BASF, Germany **A perspective of ED and Regulation in the EU** Helen McGarry, UK Health Safety Executive, UK **Epidemiology – a new perspective on root causes of observations** Gerard Swaen, Maastricht University, Netherlands
15h00–17h00	**Session 20** **Investigative Toxicology Leaders Forum (ITLF): Scientific advancements and case studies for the optimization of drug discovery** **Chairs:** Philip Hewitt, Germany | François Pognan, Switzerland **DILI revisited – key results of the IMI project MIP-DILI** Richard Weaver, Servier, France **Bile acid sequestration by cholestyramine mitigates FGFR4 inhibition-induced ALT elevation** Heiko Schadt, Novartis Pharma, Switzerland **Elucidating the role of mitochondrial dysfunction in drug-induced intrahepatic cholestasis** Sophie Penman, Servier/Liverpool University, UK **Mitochondrial toxicity in the context of hypoxia** Katie O'brien, GSK/Cambridge University, UK

19h00–0h00	Congress Dinner at Clarion Hotel

Wednesday, September 11, 2019		
08h00–13h00	Congress Registration	09h00–12h00 Exhibition
08h30–09h30	**Bo Holmstedt Memorial Fund Lecture**	
09h30–11h30	**Session 21** **Comprehensive toxicological profiles in nanoformulations for blood brain barrier** **Chairs:** Aristidis M. Tsatsakis, Greece | Petra Henrich-Noack, Germany ***In vivo* imaging of nanoparticles' effects and side effects in the healthy and diseased brain** Petra Henrich-Noack, Otto-von-Guericke University, Germany **Extracellular matrix and nanoparticles interaction – breaching new barriers?** Dragana Nikitovic, University of Crete, Greece **Amphiphilic poly-N-vinylpyrrolidone nanoparticles as drug carriers: Synthesis – Characterisation – Properties – Toxicological profile – Applications** Mikhail Shtilman, D.I. Mendeleyev University of Chemical Technology Moscow, Russia **Bio-inspired nanoparticles in neuroscience** Monica Neagu, 'Victor Babes' National Institute of Pathology Bucharest, Romania	
09h30–11h30	**Session 22** **Advancing toxicological evaluations in resolving current policy controversies in GMO products** **Chairs:** Aristidis M. Tsatsakis, Greece | Michael Antoniou, UK **Integrating multiple 'omics' analysis to study the effects of herbicide-tolerant crops** Robin Mesnage, King's Colege London, UK **Adverse outcome pathways (AOPs) and challenges in chronic studies with GMOs** Martin Wilks, University of Basel, Switzerland **Risks from genetically modified plants; past, present and the future** Gyuhwa Chung, Chonnam National University, Republic of Korea	

	Scientific challenges for GMO regulation in Europe – the EFSA GMO Panel Chair's perspective Hanspeter Naegeli, University of Zurich, Switzerland
09h30–11h30	**Session 23** **Optimization of existing and construction of new testing strategies for skin sensitization potency** **Chairs:** Dirk Petersohn, Germany | Silvia Casati, Italy **Development of performance-based test guideline for skin sensitization** Silvia Casati, European Commission, Italy **Chemical reactivity mapping of skin sensitizers in a reconstituted human epidermis model using HRMAS NMR Spectroscopy** Jean-Pierre Lepoittevin, Strasbourg University, France **A defined approach for skin sensitization potency integrating *in silico*, in chemico and *in vitro* cell data** Isabel Ferreira, University of Coimbra, Portugal **Practical application of existing and new testing strategies/defined approaches for risk assessment of cosmetic compounds** Dirk Petersohn, Henkel, Germany
09h30–11h30	**Session 24** **Toxic epidemics: why should we still be worried in 2019?** **Chairs:** Bruno Mégarbane, France | N. N. **The opioid analgesics** Bruno Mégarbane, Paris-Diderot University, France **The new psychoactive substances** Paul Dargan, Guy's and St Thomas' NHS Foundation Trust, UK **The anticholinesterasic pesticides** Michael Eddleston, University of Edinburgh, UK **The toxic alcohol** Sergey Zakharov, Prague University, Czech Republic

09h30–11h30	**Session 29** **Species specific gastrointestinal (GI) toxicity in rabbits – what does it mean for prenatal developmental toxicity (PNDT) studies and their regulatory use?** **Chairs:** Jarlath Hynes, UK | N. N. **GI toxicity in rabbit – mechanisms and relevance for human** Manon Beekhuijzen, Charles River Laboratories, Netherlands **Rabbit PNDT studies and GI toxicity; what are the regulatory consequences for plant protection products?** Mary Moxon, European Crop Protection, Belgium **Alternative species and methods for PNDT testing for pharmaceuticals** Céline Pique, Charles River Laboratories, France **Regulatory considerations for the evaluation of rabbit PNDT studies submitted under REACH and/or BPR** Ulrike Reuter, ECHA, Finland
11h30–12h00	Coffee Break & **Exhibition**
12h00–14h00	**Session 25** **Detection, assessment, management and communication of risk in mass human toxic exposures** **Chairs:** Paul Dragan, UK | Bruno Mégarbane, France **Warfare scenarios involving chemicals** Horst Thiermann, German Army Institute of Pharmacology and Toxicology, Germany **Environmental contamination by organochlorine residues: Lindane manufacture residues** Ana Ferrer-Dufol, Zaragoza University, Spain **Outbreaks by contaminated food and beverages** Sergey Zakharov, Prague University, Czech Republic **Risk communication in mass poisoning situations – what do we do, where do we go?** Charles McKay, University of Connecticut School of Medicine, US
12h00–14h00	**Session 26**

	Suitability of non-animal approaches in different industries: One size fits all? **Chairs:** Phillip Bellion, Switzerland | N. N. **Non-animal approaches in the safety assessment of food and cosmetic ingredients: similarities and differences** Phillip Bellion, DSM Nutritional Products, Switzerland **Hurdles to improve validation of alternative methods for chemicals and proposed solutions** Robert Landsiedel, BASF, Germany **Pharmaceutical Companies: alternative approaches in Research & Development versus pre-clinical toxicology. What is really used?** Richard Weaver, Servier, France **Establishing scientific credibility/validity of new approaches for different decision-making contexts** Joao Barroso, European Commission Joint Research Centre (JRC), Italy
12h00–14h00	**Session 27** **Neurotoxicity in the scientific and regulatory outlook** **Chairs:** Georges Kass, EFSA Italy | N. N. ***In vitro* model of neurotoxicity** Ellen Fritsche, Leibniz Research Institut for Environmental Medicine, Germany **Exploring chemically induced neurotoxicity mode of action** Barbara Viviani, University of Milano, Italy **Toward the regulatory application of DNT in vitro assays** Andrea Terron, European Food Safety Authority, Italy **The use of zebrafish as an alternative model for behavioural testing** Hilda Witters, Vito, Belgium
12h00–14h00	**Session 28** **Hepatotoxicity: mechanisms, new insight into liver function, and possibilities of *in vitro* prediction** ***Supported by BMBF/NWO and EU (innoSysTox and EU-ToxRisk)*** **Chairs:** Jan Hengstler, Germany | N. N.

	Insight into mechanisms of hepatotoxicity by two-photon microscopy and derivation of predictive *in vitro*/*in silico* systems Jan Hengstler, Leibniz Research Centre for Working Environment and Human Factors (IfADo), Germany **Computational modeling of cellular stress pathway activity and application in liver toxicity prediction** Joost Beltman, Leiden University, Netherlands ***In vitro* metabolome data and a comparison to the *in vivo* situation** Hennicke Kamp, BASF, Germany **Activation of cytoprotective adaptive responses in liver cells by the antibiotic nitrofurantoin** Stefan Schildknecht, University of Konstanz, Germany
14h00–14h30	**Closing Ceremony** and **Awards presentation**

Due to the very dense scientific programme you might wish to arrange your travel schedule accordingly.
In line with this, we recommend to arrange for accommodation early in advance, as the availability of a suitable hotel room might not be granted at a later stage. Detailed information can be found online: EUROTOX 2019 hotel reservation.